These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 11038141)

  • 1. Tyrosine kinase inhibitors for suppression of tumorigenic growth of Ras-transformed cells: PAK-ing in the signals.
    Gallick GE
    Cancer J; 2000; 6(4):217-9. PubMed ID: 11038141
    [No Abstract]   [Full Text] [Related]  

  • 2. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
    He H; Hirokawa Y; Levitzki A; Maruta H
    Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation.
    He H; Hirokawa Y; Manser E; Lim L; Levitzki A; Maruta H
    Cancer J; 2001; 7(3):191-202. PubMed ID: 11419027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal therapy of human pancreatic cancer and NF1-deficient breast cancer xenograft in mice by a combination of PP1 and GL-2003, anti-PAK1 drugs (Tyr-kinase inhibitors).
    Hirokawa Y; Levitzki A; Lessene G; Baell J; Xiao Y; Zhu H; Maruta H
    Cancer Lett; 2007 Jan; 245(1-2):242-51. PubMed ID: 16540233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid stimulates p21-activated kinase in vascular smooth muscle cells.
    Schmitz U; Thömmes K; Beier I; Vetter H
    Biochem Biophys Res Commun; 2002 Mar; 291(3):687-91. PubMed ID: 11855845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
    Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
    Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transforming growth factor beta signaling via Ras in mesenchymal cells requires p21-activated kinase 2 for extracellular signal-regulated kinase-dependent transcriptional responses.
    Suzuki K; Wilkes MC; Garamszegi N; Edens M; Leof EB
    Cancer Res; 2007 Apr; 67(8):3673-82. PubMed ID: 17440079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transduction pathways implicated in neural recognition molecule L1 triggered neuroprotection and neuritogenesis.
    Loers G; Chen S; Grumet M; Schachner M
    J Neurochem; 2005 Mar; 92(6):1463-76. PubMed ID: 15748164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine phosphorylation of HPK1 by activated Src promotes ischemic brain injury in rat hippocampal CA1 region.
    Li T; Yu XJ; Zhang GY
    FEBS Lett; 2008 Jun; 582(13):1894-900. PubMed ID: 18498770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AURKA inhibitors: right in time.
    Kovar H
    Pediatr Blood Cancer; 2010 Jul; 55(1):3-4. PubMed ID: 20486161
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytostatic p21 G protein-activated protein kinase gamma-PAK.
    Roig J; Traugh JA
    Vitam Horm; 2001; 62():167-98. PubMed ID: 11345898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Slaying RAS with a synthetic lethal weapon.
    Bommi-Reddy A; Kaelin WG
    Cell Res; 2010 Feb; 20(2):119-21. PubMed ID: 20118966
    [No Abstract]   [Full Text] [Related]  

  • 15. Promising new targeted agents in head and neck cancer.
    Siu LL
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S59-60. PubMed ID: 17848297
    [No Abstract]   [Full Text] [Related]  

  • 16. The anti-RAS cancer drug MKT-077 is an F-actin cross-linker.
    Maruta H; Tikoo A; Shakri R; Shishido T
    Ann N Y Acad Sci; 1999; 886():283-4. PubMed ID: 10667240
    [No Abstract]   [Full Text] [Related]  

  • 17. Implications for Src kinases in hematopoiesis: signal transduction therapeutics.
    Sinha S; Corey SJ
    J Hematother Stem Cell Res; 1999 Oct; 8(5):465-80. PubMed ID: 10791898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour-agnostic drugs and future cancer treatment.
    Børset M
    Tidsskr Nor Laegeforen; 2019 Mar; 139(5):. PubMed ID: 30872821
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical relevance of targeted interference with Src-mediated signal transduction events.
    Ly QP; Yeatman TJ
    Recent Results Cancer Res; 2007; 172():169-88. PubMed ID: 17607941
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of Ras for cancer treatment: the search continues.
    Baines AT; Xu D; Der CJ
    Future Med Chem; 2011 Oct; 3(14):1787-808. PubMed ID: 22004085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.